3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
39
Neoplasms
16
Neoplasm Metastasis
8
Colorectal Neoplasms
5
Thyroid Neoplasms
3
Skin Neoplasms
2
Recurrence
2
Leukemia, Hairy Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Histiocytosis, Langerhans-Cell
1
Heterotaxy Syndrome
1
Hepatoblastoma
1
Glioma
1
Interventions
Carboplatin
8
Paclitaxel
7
Gemcitabine
7
Irinotecan
6
Radiotherapy
4
Oxaliplatin
4
Capecitabine
4
Leucovorin
3
Fluorouracil
3
Filgrastim
3
Erlotinib Hydrochloride
3
Cisplatin
3
Bevacizumab
3
etoposide phosphate
2
Trastuzumab
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Etoposide
2
Amifostine
2
Albumin-Bound Paclitaxel
2
tipifarnib
1
tegafur-gimeracil-oteracil
1
sintilimab
1
pertuzumab
1
pemigatinib
1
pembrolizumab
1
olaparib
1
ivosidenib
1
ipatasertib
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Unknown Primary
×
Vemurafenib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts